AzTrials
AzTrials

Acute Respiratory Distress SyndromeNCT04699513

The Effect of Preemptive APRV on Patients With High Risk for ARDS

A study testing Mechanical Ventilation Mode (airway pressure release ventilation ) in people with Acute Respiratory Distress Syndrome and Intensive Care Unit, run by Karadeniz Technical University.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. Read more about this study

Who is it for?
Ages 18 to 85 years
What is being tested?
Mechanical Ventilation Mode (airway pressure release ventilation )
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
65 participants
Where
No sites listed yet
Study dates
1 May 2016to 30 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The study included patients who required invasive mechanical ventilation but was not initially diagnosed with ARDS 9, had a LIPS (Lung Injury Prediction Score) of > 7, and have been staying in the ICU for more than 24 hours.

Who cannot join

  • pregnancy
  • intracranial hypertension (suspected or confirmed by measurement with external ventricular drainage catheter)
  • severe chronic obstructive pulmonary disease or type II respiratory failure
  • confirmed bronchopleural fistula
  • documented barotrauma
  • history of pneumonectomy

About this study

Official title: The Effect of Preemptive Airway Pressure Release Ventilation on Patients With High Risk for Acute Respiratory Distress Syndrome: a Randomized Controlled Trial

Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation. Compared to the classical ventilation, APRV has been shown to provide lower peak pressure, better oxygenation, less circulatory loss, and better gas exchange without deteriorating the hemodynamic condition of the ARDS patient. This mode is believed to help to achieve the target of opening consolidated lung areas (recruitment) and to prevent repeated opening-closing of alveoli (decruitment). However, there is still insufficient and limited proof to support this hypothesis.

Recently, it has been proposed that early use of protective mechanical ventilation with APRV could be used preemptively to prevent development of ARDS in high risk patients. In that study, APRV prevented clinical and histological lung injury by protecting alveolar epithelial integrity, preserving surfactant and alveolar stability, and reducing pulmonary edema.

The primary purpose of the present study was to investigate whether early use of APRV as a lung-protecting strategy was superior to the conventional methods in a patient population with high risk of acute respiratory distress syndrome (ARDS).

Read the detailed description

This study was planned as a single-centered, prospective, and randomised-controlled study in a general intensive care unit with 18 bed capacity. The majority of the general patient population is made up of trauma and post-operative patients. The local ethics committee reviewed and approved the study protocol (protocol number: 2016/175) prior to the start of the investigation. Enrollment for the study was performed between May 2016-October 2018. Written informed consent was obtained from each patient's relatives.

Study design and sample:

The study included patients who required invasive mechanical ventilation but was not initially diagnosed with ARDS 9, had a LIPS (Lung Injury Prediction Score) of > 7 10, and have been staying in the ICU for more than 24 hours. Patient demographic properties, sedation requirements, inotrope/vasopressor levels, ARDS development status during follow-up, mechanical ventilation times, length of ICU stay, arterial blood gas results, mean airway pressure (Pmean), peak airway pressure (Ppeak) and tidal volume (Vt) in addition to the mode-specific mechanical ventilation parameters were recorded. Exclusion criteria were pregnancy, intracranial hypertension (suspected or confirmed by measurement with external ventricular drainage catheter), severe chronic obstructive pulmonary disease or type II respiratory failure, confirmed bronchopleural fistula, documented barotrauma, history of pneumonectomy, and age below 18 or above 85 years. Consecutive eligible patients were enrolled block randomization with a 1:1 allocation, randomly assigned to APRV or P-SIMV+PS groups using opaque, sealed envelopes.

Ventilator Settings:

All mechanical ventilation settings were made by intensivists, or trained residents on the night shifts. Prior to randomization, all patients were treated with VC-SIMV mode. Patients admitted during the day were ventilated in VC-SIMV mode until the main investigators evaluated the patient (1-2 hours), and patient admitted in the evening-night shift were ventilated in VC-SIMV mode until the main investigators took over the shift in the morning (maximum 16 hours). Assignment to groups was performed after calculation of LIPS score. Microprocessor-controlled mechanical ventilators (Galileo GOLD; Hamilton Medical AG, Bonaduz, Switzerland) and heated humidifiers were used as a standard in all patients. In both groups, mechanical ventilation targets were determined as maintaining plateau airway pressure (Pplateu) < 30 cmH2O and PaO2 between 60-100 mmHg or SO2>88%. In both groups, arterial blood gas measurement was performed at least twice a day. Oxygenation and respiratory mechanics were evaluated by comparing P-SIMV+PS and APRV groups at baseline and on days 1, 2, 3, and 7. Patients were followed until transfer to CPAP/T-tube and extubation, or a maximum of 28 days. During this period, follow-up was terminated once at extubation, exitus, discharge from ICU or ARDS occurred.

P-SIMV+PS group:

The reason behind using P-SIMV+PS as a conventional mode was that it is a pressure controlled mode like APRV. Pressure level was adjusted in order to get a Vt of 6-8 ml.kg-1.PBW-1 (predicted body weight). Optimal PEEP between 5-10 cmH2O was applied to all patients by titrating according to O2 requirement. Respiratory rate was adjusted as 12-15 breaths.min-1, and inspiratory time was initially adjusted to approximately 1.5 seconds. The I:E ratio was adjusted by either changing inspiratory time, respiratory rate, or both. Inspiratory triggering sensitivity was adjusted as 2 L.min-1, and was tittered by reaching the minimum level in the absence of automatic triggering.

APRV group:

Standard initial settings were Thigh / Tlow: 4/0.8 secods, Phigh: taking Pplateau value (if patient is paralyzed) or Pmean in the previous conventional method as reference, Pplateau < 30 cmH20 and target Vt 6-8 ml.kg-1.PBW-1. Plow was always set to 0 cmH2O. T-low was adjusted according to PCO2 value in blood gas measurement, by evaluating expiratory flow curve (gas flow wave form), and to get a release duration of 10-14.cycle-1. Tlow range was adjusted as 0.4-1.2 seconds. When needed, Thigh was gradually increased to 12-15 seconds by increments of 1-2 seconds. In case of hypoxemia, the problem was generally solved by increasing Phigh and FiO2, and as an additional strategy, Thigh was increased. In case of hypercapnia, sedation was lowered to allow spontaneous breaths. In order to increase the number of releases and thus, increase the minute-ventilation, Thigh was shortened and Phigh was increased 12,13.

Weaning Process:

Weaning was performed according to the European Respiratory Society Weaning Task Force recommendations in both groups 14. In APRV group, Phigh was reduced by 2-3 cmH2O and Thigh increased by 0.5-2.0 sec during weaning as the patient tolerated it. Tlow was kept constant at the same time. Before transfer to CPAP, Phigh was kept at approximately 14-16 cm H2O or lower, and Thigh was increased up to level of 10-12 sec. In P-SIMV+PS group, respiratory rate was reduced by 2 breaths.min-1, and PS level was reduced by decrements of 2-4 cmH2O. In both groups, spontaneous breathing trial was attempted for 30-60 minutes with T-tube when CPAP was 5-10 cmH2O, and patients were extubated afterwards. For patients with tolerance, the same trial was repeated the next day. Total MV time was defined as the time passed from intubation to the last successful extubation. Patients who required tracheotomy during follow-up were recorded.

Medical and Supportive Treatments:

Preferred medications for those patients requiring sedation was midazolam infused at loading dose: 0.5 to 5 mg every 1 to 5 minutes (if needed), followed by 1 to 8 mg.hour-1 or 0.01 to 0.1 mg.kg-1.hour-1 continuous infusion; titrate infusion rate to clinical effect; for analgesia, fentanyl infused at 1-2 mcg.kg-1.hr-1 i.v. The sedation goal was a Richmond Agitation Sedation Scale score of - 2 to 0 15. According to our clinic's sedation policy, Richmond Agitation Sedation Scale was assessed hourly by the nursing staff, and medication doses were titrated by the respiratory therapists according to target spontaneous respiration level. Evaluation of whether patients received sedation and the number of days which they received sedation were recorded. Sedation doses were not evaluated. None of the patients received neuromuscular blocker. Fluid management, antibiotic strategy, glucose control and enteral nutrition were also standardized between the two groups according to the ICU protocols.

Statistical Analysis On the primary outcome of developing ARDS in the light of P/F ratio 8[Clinically defined ALI/ARDS developed in the CMV group (mean [SE] PaO2/FIO2 [P/F] ratio, 242.96 [S.E. 24.82]), and this was prevented with APRV (P/F ratio, 478.00 [S.E.41.38]; P < .05 vs CMV)], power analysis using the Gpower computer program11 indicated that a total sample of 58 people would be needed to detect large effects (d: 0.888) with 90% power using a t test between means with 2-tailed alpha at .05.

All data were analyzed using IBM SPSS V23 (Chicago, USA). The Shapiro Wilk test was used to determine whether the data were normally distributed. Comparisons of data that were not normally distributed were made with the Kruskal Wallis test and the Mann Whitney U test. Categorical data were analyzed with the Pearson chi-square test. The groups were compared with regard to laboratory parameters measured on days 1, 2, 3, and 7. Non-normally distributed data were presented as median (min-max), while normally distributed data were presented as mean ± standard deviation. Categorical data were expressed as frequency and percentage. Values of p < .05 were considered significant.

Study Endpoint The primary endpoint of the study was to determine whether APRV mode was protective against ARDS compared to the conventional mode in patients with high risk of ARDS as determined by LIPS score. The secondary endpoint was to determine whether this mode provided any improvement in oxygenation, airway pressures, sedation and inotrope requirements, mechanical ventilation time and length of ICU/hospital stay.

Being tested
Mechanical Ventilation Mode (airway pressure release ventilation )
Keywords
APRV, Intensive Care Unit
Medical subject headings
Respiratory Distress Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mechanical Ventilation Mode (airway pressure release ventilation )Device

    Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.

Study groups in NCT04699513
Study groupRoleWhat they receive
P-SIMV+PS groupExperimentalThe reason behind using P-SIMV+PS as a conventional mode was that it is a pressure controlled mode like APRV.
Receives: Device: Mechanical Ventilation Mode (airway pressure release ventilation )
APRV groupExperimentalAirway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
Receives: Device: Mechanical Ventilation Mode (airway pressure release ventilation )

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ARDS

    Early use of APRV as a lung-protecting strategy was superior to the conventional methods in a patient population with high risk of acute respiratory distress syndrome (ARDS)

    Measured: 2 year

  2. P/F ratio

    Affect of early using of APRV on P/F ratio, as a lung-protecting strategy was superior to the conventional methods in a patient population with high risk of acute respiratory distress syndrome (ARDS)

    Measured: 2 year

Secondary outcomes (7)
  1. Mortality

    The secondary endpoint was to determine whether this mode provided any improvement in mortality of ICU.

    Measured: 2 year

  2. Oxygenation

    The secondary endpoint was to determine whether this mode provided any improvement in oxygenation by assessing partial pressure of oxygen in artery blood gas.

    Measured: 2 year

  3. Airway pressures

    The secondary endpoint was to determine whether this mode provided any improvement in airway pressures (mean airway pressure (Pmean), peak airway pressure (Ppeak)).

    Measured: 2 year

  4. Sedation requirements

    The secondary endpoint was to determine whether this mode provided any improvement in sedation requirements (% of present in the population).

    Measured: 2 year

  5. inotrope requirements

    The secondary endpoint was to determine whether this mode provided any improvement in inotrope requirements (% of present in the population).

    Measured: 2 year

  6. Mechanical ventilation duration in the ICU

    The secondary endpoint was to determine whether this mode provided any improvement in mechanical ventilation duration (day) in the ICU .

    Measured: 2 year

  7. Mechanical ventilation time and length of ICU/hospital stay.

    The secondary endpoint was to determine whether this mode provided any improvement in length of ICU/hospital stay (day).

    Measured: 2 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jan 2021
  2. Study start1 May 2016
  3. Primary completion30 Oct 2018
  4. Study completion30 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
a randomized controlled trial
Masking
None (open label)
Enrolment
65 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04699513
Sponsor's protocol ID
2016/175
Status last verified
Jan 2021
First submitted
4 Jan 2021
Last updated
7 Jan 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Mechanical Ventilation Mode (airway pressure release ventilation ) in people with Acute Respiratory Distress Syndrome and Intensive Care Unit, run by Karadeniz Technical University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ARDS (time frame: 2 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in